Literature DB >> 30719864

Hyperinsulinemic hypoglycemia in seven patients with de novo NSD1 mutations.

Katheryn Grand1, Christina Gonzalez-Gandolfi1, Amanda M Ackermann2,3, Deema Aljeaid4,5, Emma Bedoukian1, Lynne M Bird6, Diva D De Leon2,3, Jullianne Diaz7, Robert J Hopkin4,8, Sejal P Kadakia9, Beth Keena1, Karen O Klein9, Ian Krantz1,3, Eyby Leon7, Katherine Lord2,3, Carey McDougall1, Livija Medne1, Cara M Skraban1,3, Charles A Stanley2,3, Jennifer Tarpinian1, Elaine Zackai1,3, Matthew A Deardorff1,3, Jennifer M Kalish1,3.   

Abstract

Sotos syndrome is an overgrowth syndrome characterized by distinctive facial features and intellectual disability caused by haploinsufficiency of the NSD1 gene. Genotype-phenotype correlations have been observed, with major anomalies seen more frequently in patients with 5q35 deletions than those with point mutations in NSD1. Though endocrine features have rarely been described, transient hyperinsulinemic hypoglycemia (HI) of the neonatal period has been reported as an uncommon presentation of Sotos syndrome. Eight cases of 5q35 deletions and one patient with an intragenic NSD1 mutation with transient HI have been reported. Here, we describe seven individuals with HI caused by NSD1 gene mutations with three having persistent hyperinsulinemic hypoglycemia. These patients with persistent HI and Sotos syndrome caused by NSD1 mutations, further dispel the hypothesis that HI is due to the deletion of other genes in the deleted 5q35 region. These patients emphasize that NSD1 haploinsufficiency is sufficient to cause HI, and suggest that Sotos syndrome should be considered in patients presenting with neonatal HI. Lastly, these patients help extend the phenotypic spectrum of Sotos syndrome to include HI as a significant feature.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  NSD1; Sotos syndrome; hyperinsulinism; hypoglycemia; overgrowth syndrome; sacrococcygeal teratoma

Mesh:

Substances:

Year:  2019        PMID: 30719864      PMCID: PMC6454923          DOI: 10.1002/ajmg.a.61062

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  19 in total

1.  Hyperinsulinemic hypoglycemia in a patient with an intragenic NSD1 mutation.

Authors:  Pilar Carrasco Salas; Carmen Palma Milla; José Miguel Lezana Rosales; Carmen Benito; Sara Franco Freire; Juan López Siles
Journal:  Am J Med Genet A       Date:  2015-10-21       Impact factor: 2.802

Review 2.  Sotos syndrome 1 and 2.

Authors:  Juan F Sotos
Journal:  Pediatr Endocrinol Rev       Date:  2014-09

3.  Hyperinsulinemic hypoglycemia of infancy in Sotos syndrome.

Authors:  Terumichi Matsuo; Kenji Ihara; Masayuki Ochiai; Tadamune Kinjo; Yoko Yoshikawa; Kanako Kojima-Ishii; Marie Noda; Hiroshi Mizumoto; Maiko Misaki; Kyoko Minagawa; Koji Tominaga; Toshiro Hara
Journal:  Am J Med Genet A       Date:  2012-12-13       Impact factor: 2.802

4.  Hyperinsulinemic hypoglycemia in Beckwith-Wiedemann, Sotos, and Kabuki syndromes: A nationwide survey in Japan.

Authors:  Naoko Toda; Kenji Ihara; Kanako Kojima-Ishii; Masayuki Ochiai; Kazuhiro Ohkubo; Yutaka Kawamoto; Yoshinori Kohno; Sakae Kumasaka; Akihiko Kawase; Yasuhisa Ueno; Takeshi Futatani; Tokuo Miyazawa; Yuko Nagaoki; Setsuko Nakata; Maiko Misaki; Hiroko Arai; Masahiko Kawai; Maki Sato; Yukari Yada; Nobuhiro Takahashi; Atsushi Komatsu; Kanemasa Maki; Shinichi Watabe; Yutaka Sumida; Makoto Kuwashima; Hiroshi Mizumoto; Kazuo Sato; Toshiro Hara
Journal:  Am J Med Genet A       Date:  2016-11-07       Impact factor: 2.802

5.  2000 CDC Growth Charts for the United States: methods and development.

Authors:  Robert J Kuczmarski; Cynthia L Ogden; Shumei S Guo; Laurence M Grummer-Strawn; Katherine M Flegal; Zuguo Mei; Rong Wei; Lester R Curtin; Alex F Roche; Clifford L Johnson
Journal:  Vital Health Stat 11       Date:  2002-05

6.  A case with neonatal hyperinsulinemic hypoglycemia: It is a characteristic complication of Sotos syndrome.

Authors:  Yoshie Nakamura; Masaki Takagi; Hiroshi Yoshihashi; Masaru Miura; Satoshi Narumi; Tomonobu Hasegawa; Yoshishige Miyake; Yukihiro Hasegawa
Journal:  Am J Med Genet A       Date:  2015-02-25       Impact factor: 2.802

Review 7.  A clinical study of Sotos syndrome patients with review of the literature.

Authors:  George Leventopoulos; Sophia Kitsiou-Tzeli; Konstantinos Kritikos; Stavroula Psoni; Ariadni Mavrou; Emmanuel Kanavakis; Helen Fryssira
Journal:  Pediatr Neurol       Date:  2009-05       Impact factor: 3.372

8.  Single-Cell Transcriptomics of the Human Endocrine Pancreas.

Authors:  Yue J Wang; Jonathan Schug; Kyoung-Jae Won; Chengyang Liu; Ali Naji; Dana Avrahami; Maria L Golson; Klaus H Kaestner
Journal:  Diabetes       Date:  2016-06-30       Impact factor: 9.461

9.  Cerebral gigantism: endocrinological and clinical observations of six patients including a congenital giant, concordant monozygotic twins, and a child who acheived adult gigantic size.

Authors:  E B Hook; J W Reynolds
Journal:  J Pediatr       Date:  1967-06       Impact factor: 4.406

10.  Integration of ATAC-seq and RNA-seq identifies human alpha cell and beta cell signature genes.

Authors:  Amanda M Ackermann; Zhiping Wang; Jonathan Schug; Ali Naji; Klaus H Kaestner
Journal:  Mol Metab       Date:  2016-01-11       Impact factor: 7.422

View more
  3 in total

Review 1.  Congenital hyperinsulinism disorders: Genetic and clinical characteristics.

Authors:  Elizabeth Rosenfeld; Arupa Ganguly; Diva D De Leon
Journal:  Am J Med Genet C Semin Med Genet       Date:  2019-08-14       Impact factor: 3.908

2.  Localized islet nuclear enlargement hyperinsulinism (LINE-HI) due to ABCC8 and GCK mosaic mutations.

Authors:  Kara E Boodhansingh; Zhongying Yang; Changhong Li; Pan Chen; Katherine Lord; Susan A Becker; Lisa J States; N Scott Adzick; Tricia Bhatti; Show-Ling Shyng; Arupa Ganguly; Charles A Stanley; Diva D De Leon
Journal:  Eur J Endocrinol       Date:  2022-06-27       Impact factor: 6.558

Review 3.  Congenital Hyperinsulinism: Current Laboratory-Based Approaches to the Genetic Diagnosis of a Heterogeneous Disease.

Authors:  Thomas I Hewat; Matthew B Johnson; Sarah E Flanagan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-07       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.